Endocrinol Metab.  2020 Mar;35(1):95-96. 10.3803/EnM.2020.35.1.95.

A Brief Overview of the Epidemiology of Pheochromocytoma and Paraganglioma in Korea

• Choi YM

• KMID: 2471724
• DOI: http://doi.org/10.3803/EnM.2020.35.1.95

Abstract

No abstract available.

MeSH Terms

Epidemiology*
Korea*
Paraganglioma*
Pheochromocytoma*

Reference

1. Burnichon N, Buffet A, Gimenez-Roqueplo AP. Pheochromocytoma and paraganglioma: molecular testing and personalized medicine. Curr Opin Oncol. 2016; 28:5–10. PMID: 26599293.

2. DeLellis RA. World Health Organization Classification of tumors. Pathology and genetics of tumours of endocrine organs. Lyon: IARC;2004.

3. Fishbein L. Pheochromocytoma and paraganglioma: genetics, diagnosis, and treatment. Hematol Oncol Clin North Am. 2016; 30:135–150. PMID: 26614373.

4. Lenders JWM, Eisenhofer G. Update on modern management of pheochromocytoma and paraganglioma. Endocrinol Metab (Seoul). 2017; 32:152–161. PMID: 28685506.

5. Kim J, Bae KH, Choi YK, Jeong JY, Park KG, Kim JG, et al. Clinical characteristics for 348 patients with adrenal incidentaloma. Endocrinol Metab (Seoul). 2013; 28:20–25. PMID: 24396646.

6. The Korean Endocrine Society. Korean Endocrine rare disease fact sheet 2018 [Internet]. Seoul: The Korean Endocrine Society;2018. cited 2020 Feb 24. Available from: https://www.endocrinology.or.kr/.

7. Kim JH, Moon H, Noh J, Lee J, Kim SG. Epidemiology and prognosis of pheochromocytoma/paraganglioma in Korea: a nationwide study based on the National Health Insurance Service. Endocrinol Metab (Seoul). 2020; 35:157–164.

8. Beard CM, Sheps SG, Kurland LT, Carney JA, Lie JT. Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc. 1983; 58:802–804. PMID: 6645626.

9. Stenstrom G, Svardsudd K. Pheochromocytoma in Sweden 1958-1981. An analysis of the National Cancer Registry Data. Acta Med Scand. 1986; 220:225–232. PMID: 3776697.

10. Berends AMA, Buitenwerf E, de Krijger RR, Veeger NJGM, van der Horst-Schrivers ANA, Links TP, et al. Incidence of pheochromocytoma and sympathetic paraganglioma in the Netherlands: a nationwide study and systematic review. Eur J Intern Med. 2018; 51:68–73. PMID: 29361475.

11. Kim KY, Kim JH, Hong AR, Seong MW, Lee KE, Kim SJ, et al. Disentangling of malignancy from benign pheochromocytomas/paragangliomas. PLoS One. 2016; 11:e0168413. PMID: 27992508.

12. Choi YM, Sung TY, Kim WG, Lee JJ, Ryu JS, Kim TY, et al. Clinical course and prognostic factors in patients with malignant pheochromocytoma and paraganglioma: a single institution experience. J Surg Oncol. 2015; 112:815–821. PMID: 26464058.

13. Crona J, Taieb D, Pacak K. New perspectives on pheochromocytoma and paraganglioma: toward a molecular classification. Endocr Rev. 2017; 38:489–515. PMID: 28938417.